神盾局特工

Pfizer cuts full-year outlook due to declining sales of Covid-19-related products_我的网站

A |     Shares of Pfizer are in retreat on the first day of trading after the drug company said sales of its COVID-19 vaccine and its coronavirus treatment are weaker than it had expected and cut revenue projections by $9 billion for the year. Falling sales of both clipped sales in the second quarter, but Pfizer said in August that it expected a rebound in the second half of 2023. Shares of Pfizer slipped more than 1% before the opening bell Monday and Moderna, which is heavily reliant on the competing vaccine it makes, slid nearly 5%. Pfizer said Friday that global usage of Paxlovid is trending slightly above last year, but that it's still below expectations.The fall vaccination period just began and the New York City drugmaker said that it's too soon to get a handle on vaccination rates for the year.Full-year revenue for Paxlovid and Comirnaty is expected to be approximately $12.5 billion, short $9 billion of what it had expected. Pfizer is lowering its full-year revenue expectations for Paxlovid by approximately $7 billion. That number also accounts for delayed commercialization of the product, which was pushed to January 2024 from the company's previous expectation of commercialization in the second half of this year. Pfizer is also lowering its 2023 revenue expectations for Comirnaty by approximately $2 billion due to lower-than-expected vaccination rates.Pfizer Inc. now foresees 2023 revenue in a range of $58 billion to $61 billion, down from its prior forecast for $67 billion to $70 billion. It now projects full-year adjusted earnings between $1.45 and $1.65 per share due to lower-than-anticipated revenue for COVID-19-related products and inventory write-offs.That is short of the full-year revenue of $63.61 billion and earnings of $2.77 per share that Wall Street was expecting, and far short of the company's previous projections of per-share earning between $3.25 and $3.45. JPMorgan said the company's update solves an ongoing U.S. Paxlovid inventory debate and it anticipates the company's bigger-than-expected cuts to its sales projections will help put a floor under per-share earnings expectations for next year.。    　　兰州8月21日电 (戴文昌)甘肃省白银市委常委、常务副市长葛永宏21日表示，作为享誉全国的老工业基地，该市“十五五”时期将围绕打造“三地一极”发展格局，以发展新质生产力为引领，重点打好工业“焕新牌”、农业“特色牌”、服务业“提质牌”，以“三牌联打”构建现代化产业体系。2025年3月31日，白银市年产20万吨高导新材料项目生产车间。(资料图)(无人机照片) 戴文昌 摄　　白银地处黄河上游，因矿设企、因企设市，是一座以贵金属命名的城市，曾创造了铜产量、产值、利税连续18年全国第一的辉煌业绩，被称为“铜城”。目前，该市规上工业产值达到1318亿元，农业全产业链产值达到450亿元，工业家底更厚实、产业筋骨更强健。　　工业是白银的家底，也是转型升级的主战场。白银为打好工业“焕新牌”，让“老基地”迸发“新动能”，将紧扣高端化、智能化、绿色化方向，加快推动有色、化工、能源、建材等传统产业焕新升级，让传统产业“老树发新芽”，新兴产业也在“新芽成大树”。　　在改造提升传统产业的同时，白银把目光投向更广阔的新赛道，持续做大做强新材料、“新能源+”、生物医药、装备制造、低空经济等新兴产业，打造全省重要的新兴产业集聚区；抢占长时储能、人工智能、生物制造等未来产业新赛道，力争工业增加值年均增长10%以上，打造全省现代工业产业集聚地。　　黄河流经白银258公里，建成被称为“中华之最”的景电等大中型灌区，为打好农业“特色牌”，让“土特产”成为“大产业”，白银将以工业思维谋划农业，实施粮食单产提升工程，粮食总产量稳定在100万吨以上，把饭碗牢牢端在自己手中。图为白银市国家文冠果现代农业全产业链标准化示范基地。(资料图)(无人机照片) 戴文昌 摄　　“十五五”期间，为做足“农头工尾、粮头食尾、畜头肉尾”文章，白银市重点发展牛羊、瓜菜、枸杞、文冠果、小杂粮等特色产业，力争产值突破600亿元。

B | 葛永宏说，同时做强“靖远羊羔肉”“景泰条山梨”等区域公用品牌，让白银更多优质农产品走向全国。　　在此基础上，白银依托全国现代商贸流通体系试点，加快构建“一核三带五节点”现代物流体系；做强科技研发、检验检测等工业服务业；提升生活性服务业品质，擦亮“黄河之上·多彩白银”文旅品牌，打好服务业“提质牌”，让“软支撑”变为“硬实力”。　　葛永宏表示，未来，白银将以科技创新与产业创新深度融合为支撑，以新型工业化为主导，以一二三产耦合协同为路径，加快建设现代化产业体系，为老工业基地转型升级探索“白银路径”。

Current article:http://wakn.suilaoheirenzhaizhaikang.sbs/news/20260826_53010.html

Published on:08:10:24